Literature DB >> 30707305

Old drugs still work! Oral etoposide in a relapsed medulloblastoma.

Marta Perez-Somarriba1, Maitane Andión1, Miguel A López-Pino2, Cinzia Lavarino3, Luis Madero1, Alvaro Lassaletta4.   

Abstract

Medulloblastoma is the most common malignant brain tumor in children. Approximately 30% of children with medulloblastoma will progress or relapse despite being treated. New therapies have been proposed in recent years, including high-dose chemotherapy, immunotherapy, and targeted therapy. However, the best treatment for these patients remains unclear, and in this situation prognosis is poor. Oral etoposide has been used as a single agent or in combination for treating relapsed brain tumors since the 1990s. We report an 8-year-old patient with recurrent metastatic medulloblastoma who had an excellent response after treatment with oral etoposide, maintaining a great quality of life. As clinicians, we must always try to include our patients in clinical trials; however, when this is not possible, we should not forget that "old drugs" such as oral etoposide may work in some patients, with a good response of the tumor, and what is most important, providing the patient with a good quality of life.

Entities:  

Keywords:  Chemotherapy; Children; Oral etoposide; Relapsed medulloblastoma

Mesh:

Substances:

Year:  2019        PMID: 30707305     DOI: 10.1007/s00381-019-04072-9

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  22 in total

1.  Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.

Authors:  Andreas Peyrl; Monika Chocholous; Mark W Kieran; Amedeo A Azizi; Christina Prucker; Thomas Czech; Karin Dieckmann; Maria-Theresa Schmook; Christine Haberler; Ulrike Leiss; Irene Slavc
Journal:  Pediatr Blood Cancer       Date:  2011-12-06       Impact factor: 3.167

2.  A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group.

Authors:  Adam J Esbenshade; Mehmet Kocak; Linda Hershon; Pierre Rousseau; Jean-Claude Decarie; Susan Shaw; Peter Burger; Henry S Friedman; Amar Gajjar; Albert Moghrabi
Journal:  Pediatr Blood Cancer       Date:  2016-12-21       Impact factor: 3.167

3.  Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).

Authors:  A Davidson; R Gowing; S Lowis; D Newell; I Lewis; C Dicks-Mireaux; C R Pinkerton
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

4.  A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.

Authors:  Soledad Gómez; Alícia Garrido-Garcia; Laura Garcia-Gerique; Isadora Lemos; Mariona Suñol; Carmen de Torres; Marta Kulis; Sara Pérez-Jaume; Ángel M Carcaboso; Betty Luu; Mark W Kieran; Nada Jabado; Alexey Kozlenkov; Stella Dracheva; Vijay Ramaswamy; Volker Hovestadt; Pascal Johann; David T W Jones; Stefan M Pfister; Andrés Morales La Madrid; Ofelia Cruz; Michael D Taylor; Jose-Ignacio Martin-Subero; Jaume Mora; Cinzia Lavarino
Journal:  Clin Cancer Res       Date:  2018-01-19       Impact factor: 12.531

5.  Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols.

Authors:  Girish Dhall; Howard Grodman; Lingyun Ji; Stephen Sands; Sharon Gardner; Ira J Dunkel; Geoffrey B McCowage; Blanca Diez; Jeffrey C Allen; Anjali Gopalan; Albert S Cornelius; Amanda Termuhlen; Minnie Abromowitch; Richard Sposto; Jonathan L Finlay
Journal:  Pediatr Blood Cancer       Date:  2008-06       Impact factor: 3.167

6.  Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.

Authors:  N J Winick; R W McKenna; J J Shuster; N R Schneider; M J Borowitz; W P Bowman; D Jacaruso; B A Kamen; G R Buchanan
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

7.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

8.  A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.

Authors:  Nathan J Robison; Federico Campigotto; Susan N Chi; Peter E Manley; Christopher D Turner; Mary Ann Zimmerman; Christine A Chordas; Annette M Werger; Jeffrey C Allen; Stewart Goldman; Joshua B Rubin; Michael S Isakoff; Wilbur J Pan; Ziad A Khatib; Melanie A Comito; Anne E Bendel; Jay B Pietrantonio; Laura Kondrat; Shannon M Hubbs; Donna S Neuberg; Mark W Kieran
Journal:  Pediatr Blood Cancer       Date:  2013-10-04       Impact factor: 3.167

9.  Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.

Authors:  Edward C Schwalbe; Janet C Lindsey; Sirintra Nakjang; Stephen Crosier; Amanda J Smith; Debbie Hicks; Gholamreza Rafiee; Rebecca M Hill; Alice Iliasova; Thomas Stone; Barry Pizer; Antony Michalski; Abhijit Joshi; Stephen B Wharton; Thomas S Jacques; Simon Bailey; Daniel Williamson; Steven C Clifford
Journal:  Lancet Oncol       Date:  2017-05-22       Impact factor: 41.316

Review 10.  Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.

Authors:  Francisco Bautista; Victoria Fioravantti; Teresa de Rojas; Fernando Carceller; Luis Madero; Alvaro Lassaletta; Lucas Moreno
Journal:  Cancer Med       Date:  2017-10-04       Impact factor: 4.452

View more
  3 in total

1.  [Risk factors for recurrence within 2 years in children with medulloblastoma].

Authors:  Jing-Jing Liu; Yan-Ling Sun; Shu-Xu DU; Chun-De Li; Xiao-Jun Gong; Miao Li; Wan-Shui Wu; Li-Ming Sun
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-08

Review 2.  Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.

Authors:  Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.575

Review 3.  Temozolomide and oral etoposide in children with recurrent malignant brain tumors.

Authors:  Antonio Ruggiero; Anna Ariano; Silvia Triarico; Michele Antonio Capozza; Alberto Romano; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà
Journal:  Drugs Context       Date:  2020-06-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.